following a full submission assessed under the end of life and orphan equivalent medicine process:
pembrolizumab (Keytruda®) is accepted for restricted use within NHSScotland.
Indication under review: In combination with lenvatinib, for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.
SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule.
Pembrolizumab in combination with lenvatinib improved progression-free and overall survival compared with chemotherapy in patients with advanced or recurrent endometrial cancer who had disease progression on or after platinum-based chemotherapy.
This SMC advice takes account of the benefit of Patient Access Schemes (PAS) that improve the cost effectiveness of pembrolizumab and lenvatinib. This advice is contingent upon the continuing availability of these PAS in NHS Scotland or list prices that are equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice781KB (PDF)
- Medicine name:
- pembrolizumab (Keytruda)
- SMC ID:
Pembrolizumab in combination with lenvatinib, for the treatement of advanced or recurrent endometrial carcinoma (EC) in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 10 October 2022